travellinglight/iStock via Getty Images
- A Data and Safety Monitoring Board has recommended that Cassava Sciences (NASDAQ:SAVA) continue its phase 3 program for its Alzheimer's candidate simufilam.
- CEO Remi Barbier noted that top-line efficacy data for the 12-month study is due later this year.
- The board is only charged with reviewing safety, not efficacy.